Merck voices commitment to advancing MS treatments

Merck’s launch of a new product emphasises the firm’s commitment to advancing multiple sclerosis (MS) treatments, it has stated.

The RebiSmart is an individually adjustable electronic injection device that has been approved and introduced in Europe, as well as Canada.

By operating the product, patients can self-administer Merck’s disease-modifying drug Rebif (interferon beta-1a) that is used to manage relapsing forms of MS.

The device, which is the first of its kind designed for this purpose, has unique features to help users receive the full benefit from their treatment.

Patients are guided through the injection process via interactive, on-screen instructions, while discomfort and pain is minimised by adjustable comfort settings that offer flexibility with injection duration and depth.

Executive vice-president of Merck Serono’s European commercial division Dr Roberto Gradnik said the product is easy-to-use and commented on the creation of the device.

“Patients and healthcare professionals were involved in the design of RebiSmart – and their feedback was extremely valuable for developing an innovative device that really meets their needs,” he commented.

Merck currently employs around 33,000 staff in 59 countries.